Research square · 2026
Age as a biological stratifier for immune checkpoint inhibitor response in ovarian cancer.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Petta Tirzah Braz, Kwock Kathy, Roman Lynda, Carlson Joseph W
Аннотация
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy produces response rates of only 8-15% in ovarian cancer, widely considered ICI-refractory. However, DNA damage sensing and interferon signaling undergo pronounced age-dependent remodeling, making patient age a plausible modifier of ICI response.
METHODS: We integrated four ovarian cancer transcriptomic cohorts (n = 761) and tested the age-by-BRCA-immune interaction by pre-specified random-effects meta-analysis, comparing Young (< 50 y) versus Old (≥ 60 y) patients with the peri- and early post-menopausal transition (50-59 y) excluded from primary comparisons. Age-dependent expression of cGAS, STING1, IFI16, and IDO1 was quantified. A single-institution ICI-treated cohort (USC/LAGMC, n = 20; Responder defined as progression-free interval ≥ 365 days) provided clinical anchoring.
RESULTS: Patient age reversed the BRCA-immune relationship across all four cohorts (pooled interaction b = -0.275, 95% CI - 0.502 to - 0.048, p = 0.018, I2=0%). STING1 was reduced in older patients across three platforms (TCGA-OV FDR = 0.014; GSE9891 p = 0.0026; GSE140082 p = 6.5×10-7), together with the nuclear DNA sensor IFI16 (TCGA-OV FDR = 0.018; GSE140082 p = 0.007), while upstream cGAS was unchanged (p = 0.771). Downstream IDO1 was concurrently reduced (p = 0.009). Tumor mutational burden, HRD status, BRCA1 methylation, and an eight-gene checkpoint panel did not account for the age signal. Clinically, patients ≥ 60 y achieved 75% response versus 14% in patients < 50 y (Fisher p = 0.041), independent of BRCA status.
CONCLUSIONS: Patient age is a biological determinant of the ovarian cancer immune microenvironment through selective STING1/IFI16 attenuation with cGAS preserved. These findings support a systematic reanalysis of existing ovarian cancer ICI clinical trial data stratified by patient age.
METHODS: We integrated four ovarian cancer transcriptomic cohorts (n = 761) and tested the age-by-BRCA-immune interaction by pre-specified random-effects meta-analysis, comparing Young (< 50 y) versus Old (≥ 60 y) patients with the peri- and early post-menopausal transition (50-59 y) excluded from primary comparisons. Age-dependent expression of cGAS, STING1, IFI16, and IDO1 was quantified. A single-institution ICI-treated cohort (USC/LAGMC, n = 20; Responder defined as progression-free interval ≥ 365 days) provided clinical anchoring.
RESULTS: Patient age reversed the BRCA-immune relationship across all four cohorts (pooled interaction b = -0.275, 95% CI - 0.502 to - 0.048, p = 0.018, I2=0%). STING1 was reduced in older patients across three platforms (TCGA-OV FDR = 0.014; GSE9891 p = 0.0026; GSE140082 p = 6.5×10-7), together with the nuclear DNA sensor IFI16 (TCGA-OV FDR = 0.018; GSE140082 p = 0.007), while upstream cGAS was unchanged (p = 0.771). Downstream IDO1 was concurrently reduced (p = 0.009). Tumor mutational burden, HRD status, BRCA1 methylation, and an eight-gene checkpoint panel did not account for the age signal. Clinically, patients ≥ 60 y achieved 75% response versus 14% in patients < 50 y (Fisher p = 0.041), independent of BRCA status.
CONCLUSIONS: Patient age is a biological determinant of the ovarian cancer immune microenvironment through selective STING1/IFI16 attenuation with cGAS preserved. These findings support a systematic reanalysis of existing ovarian cancer ICI clinical trial data stratified by patient age.